Franks C R, Curtis K, Perkins F T
Br J Cancer. 1973 May;27(5):390-5. doi: 10.1038/bjc.1973.46.
During studies of the ability of antilymphocyte serum (ALS) to suppress the immune mechanism of mice and thereby allow HeLa cells to grow into a large tumour in the mice, it was observed that many tumours continued to grow even after the ALS treatment had been stopped and full immunological competence of the mice had returned. The HeLa cells of such tumours appeared to be unchanged in their ability to induce further tumours in ALS treated mice to which they were transferred and, furthermore, the mice which were carrying such tumours in the presence of immunological competence were able to reject additional injections of HeLa cells or other human tumour cells. The four possible explanations for this phenomenon, (i) depression of cellular response; (ii) local reaction at the graft site; (iii) the presence of a blocking factor; and (iv) the elevation of the humoral response, have been investigated.
在研究抗淋巴细胞血清（ALS）抑制小鼠免疫机制从而使海拉细胞在小鼠体内长成大肿瘤的能力时，观察到许多肿瘤即使在停止ALS治疗且小鼠恢复完全免疫能力后仍继续生长。这种肿瘤的海拉细胞在被转移到经ALS处理的小鼠体内诱导进一步肿瘤的能力方面似乎没有变化，此外，在具有免疫能力的情况下携带此类肿瘤的小鼠能够排斥额外注射的海拉细胞或其他人类肿瘤细胞。针对这一现象的四种可能解释，即（i）细胞反应抑制；（ii）移植部位的局部反应；（iii）存在阻断因子；以及（iv）体液反应增强，均已进行了研究。
